Expert Financial Analysis and Reporting

Key Points: Antares has an impressive portfolio of seven new products that could lead to explosive growth over the next four years. I am projecting that revenues of five partnered products could increase from $17.0 million in 2016 to $142.0 million in 2021 (a nearly five fold increase) and that revenues from two wholly owned […]

Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this was explained in my April 22, 2016  report “An Outstanding Product Pipeline Promises Dramatic Growth Through 2022” (see this link)  If you are unfamiliar with the Company or need to be refreshed, I would suggest […]

Investment Thesis in Brief If you like numbers, you will like this report. It is a very detailed analysis of the contribution to Antares sales and profits of 7 new products that will drive growth in coming years. As summarized in the following table, I am looking for Antares to roughly breakeven in 2017 and […]

Investment Thesis Investment Overview The launch of Otrexup has been extremely disappointing in contrast to my high expectations. Medac launched a competitive product Rasuvo shortly after Otrexup. It was my expectation that Medac would focus on educating physicians and expanding the market to the benefit of both products. In my experience, this has been the […]

Introduction Antares recently updated its corporate presentation on their website. .There were several slides in the presentation that reinforce my confidence in my positive investment outlook which is based on three key components: (1) the Otrexup launch gaining traction, (2) approval of an AB rated generic version of EpiPen and (3) a deep and promising […]

Introduction to Report One of my assets is also one of my biggest drawbacks. When I am writing on a Company I start out thinking that I have a good understanding of the Company, but inevitably as I dig deeper, I find out that the more information I gather the more questions that arise in […]

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

SmithOnStocks Mailbox About the Mailbox: My mailbox comments are brief articles on stocks in which I am involved. These can come from recent events or from subscribers’ questions. They are meant to address specific issues about these stocks and are not full and balanced reports. Please refer to the Reports section of my website for […]

SmithOnStocks Mailbox April 28, 2015 A Quick Take on Recent Events If you have a question for the mailbox, contact me. Purpose of this Note I have written extensively on Antares, Agenus, Cytokinetics and Discovery Laboratories. I have Buys on Antares, Agenus and Cytokinetics. I have a Hold on Discovery (what a troubled history), but […]

Overview Subsequent to my posting of my recent update on Antares, I have seen that Teva has made an offer to buy Mylan; Mylan, of course, markets EpiPen. My first reaction to this news was alarm suggesting that Teva would abandon the AB rated product and focus on the branded product. However, this is highly […]